Dem Donor Alleges That Joe Biden Was Doped Up Before Campaign Events
Are We Shocked a CBS News Host Decided to Spread USAID Propaganda?
CNN's Harry Enten Explains Why Trump's Favorability Ratings Are Much Better This Time
Blue States Plotted Their War Against Trump Three Days After the 2024 Election....
Secretary of Defense Hegseth Ends the Woke Games at Fort Bragg
Tom Homan Has a Clue Where the ICE Leaks Are Coming From...and It's...
Trump Broke These People
Trump and Musk Are Spring Cleaning the Government
'Mr. President, May I Drive the Bulldozer?'
Strengthen Iran Policy by Amplifying Iranian Calls for Democracy
What Is It the Democrats Are Afraid of?
The Path Forward for the Trump-Era Federal Trade Commission
DOGE Uncovers $50B Annually Sent to People Without SSNs—Why Didn't Congress Reveal This?
Decreasing Wildfire Devastation Requires Permitting Reform
USAID: To Have or Not to Have
Tipsheet

FDA Panel Recommends Johnson & Johnson's One-Dose COVID Vaccine for Approval

AP Photo/Andrew Harnik

More good news on the coronavirus front. A panel of FDA advisors voted unanimously on Friday to recommend the agency approve drugmaker Johnson & Johnson's one-dose coronavirus vaccine in the United States. Following the recommendation by the FDA’s Vaccines and Related Biological Products Advisory Committee, the FDA is expected to approve the vaccine for emergency use in the coming days. 

Advertisement

Johnson & Johnson's vaccine will be the third coronavirus vaccine to receive FDA approval, but the first vaccine requiring just one shot for vaccination. The drug showed a 66 percent effectiveness against moderate to severe COVID-19 infections and about an 85 percent effectiveness against the most serious illnesses. While two other FDA-approved vaccines have efficacy rates in the 90s, Johnson & Johnson's drug was shown to prevent 100 percent of hospitalizations in a clinical study of around 44,000 participants in the United States. 

"This is a vaccine to prevent you from going to the hospital and dying at a level that’s certainly comparable" to the Pfizer and Moderna vaccines, said Dr. Paul Offit, a member of the FDA's advisory panel and vaccine expert at Children's Hospital of Philadelphia.

Unlike the vaccines developed by Pfizer and Moderna, Johnson & Johnson's vaccine candidate does not to be stored in freezers and remains stable for months in refrigerated temperatures.  

Advertisement

In the United States, over 44 million Americans have received at least one dose of the two-dose vaccines developed by Pfizer and Moderna, according to the AP. Nearly 20 million Americans have now received both doses. 

Around 3 to 4 million doses of the new vaccine are expected to be shipped out next week if the drug receives emergency-use approval from the FDA. The company has pledged to deliver some 20 million doses by April and 100 million by late June. 

Approval may come as early as this weekend. 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement